Bryostatin

Dr. Daniel Alkon, the chief scientific officer at Neurotrope Inc (NASDAQ: NTRP), discussed the fight against Alzheimer's disease in an interview with Benzinga.  Benzinga: What is bryostatin, and how is it used for the treatment in patients with moderate to severe Alzheimer's disease?...

On Wednesday, TheStreet biotech reporter Adam Feuerstein raised alarm that an unknown source paid to convert Seeking Alpha posts about Neurotrope Inc (NASDAQ: NTRP) into unofficial promotional pieces for bryostatin, the company's lead drug candidate. Neurotrope denied any involvement. "The...

Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday after a planned release of clinical data failed to impress investors. Investors On A...

After hearing Neurotrope Inc (NASDAQ: NTRP) would announce results of its Phase 2 study of potential Alzheimer’s Disease (AD) treatment Bryostatin-1, biotech investors have waited with baited breath through the weekend. On Monday, Neurotrope reported positive top-line results from its Phase 2...

Shares of Neurotrope Inc (NASDAQ: NTRP), a clinical-stage biopharmaceutical company that develops therapies for the treatment of Alzheimer's and neurodegenerative diseases, shot higher by more than 15 percent early Friday morning. Neurotrope announced it will be releasing Monday top-line data...

Neurotrope Inc (OTC: NTRP) was caught with other biotechs in a harsh, broad market selloff Tuesday that saw all major indices close lower. The company focuses on developing therapies for neurodegenerative diseases, most notably Alzheimer's Disease. Neurotrope has this in common with Anavex Life...

Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people with mild to moderate Alzheimer's disease (AD) after it was determined it had "virtually no chance of finding a positive clinical effect." In light...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

Neurotrope Inc (OTC: NTRP), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the...